Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2.
van Helden J, Butler CD, Achaz G, Canard B, Casane D, Claverie JM, Colombo F, Courtier V, Ebright RH, Graner F, Leitenberg M, Morand S, Petrovsky N, Segreto R, Decroly E, Halloy J. van Helden J, et al. Among authors: petrovsky n. Lancet. 2021 Oct 16;398(10309):1402-1404. doi: 10.1016/S0140-6736(21)02019-5. Epub 2021 Sep 17. Lancet. 2021. PMID: 34543608 Free PMC article. No abstract available.
Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection.
Li L, Honda-Okubo Y, Huang Y, Jang H, Carlock MA, Baldwin J, Piplani S, Bebin-Blackwell AG, Forgacs D, Sakamoto K, Stella A, Turville S, Chataway T, Colella A, Triccas J, Ross TM, Petrovsky N. Li L, et al. Among authors: petrovsky n. Vaccine. 2021 Sep 24;39(40):5940-5953. doi: 10.1016/j.vaccine.2021.07.087. Epub 2021 Aug 3. Vaccine. 2021. PMID: 34420786 Free PMC article.
Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations.
Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, Roshanzamir K, Bayatani B, Taheri A, Petrovsky N, Li L, Barati S. Tabarsi P, et al. Among authors: petrovsky n. Clin Microbiol Infect. 2022 Sep;28(9):1263-1271. doi: 10.1016/j.cmi.2022.04.004. Epub 2022 Apr 15. Clin Microbiol Infect. 2022. PMID: 35436611 Free PMC article. Clinical Trial.
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial.
Tabarsi P, Anjidani N, Shahpari R, Roshanzamir K, Fallah N, Andre G, Petrovsky N, Barati S. Tabarsi P, et al. Among authors: petrovsky n. Immunology. 2022 Nov;167(3):340-353. doi: 10.1111/imm.13540. Epub 2022 Jul 13. Immunology. 2022. PMID: 35758850 Free PMC article. Clinical Trial.
Artificial Intelligence in Vaccine and Drug Design.
Thomas S, Abraham A, Baldwin J, Piplani S, Petrovsky N. Thomas S, et al. Among authors: petrovsky n. Methods Mol Biol. 2022;2410:131-146. doi: 10.1007/978-1-0716-1884-4_6. Methods Mol Biol. 2022. PMID: 34914045
291 results